Therefore, the results herein suggest that IL-1β signaling mediates hepatocyte TG accumulation by driving the denovo lipogenic signaling pathway in obese mouse livers and that IL-1β represents a promising therapeutic target in the treatment of obesity-induced NAFLD. The gene discussed is IL1B; the disease is obesity disorder.